Download full-text PDF

Source
http://dx.doi.org/10.1016/0140-6736(92)92267-jDOI Listing

Publication Analysis

Top Keywords

pefloxacin first-line
4
first-line treatment
4
treatment nephrotic
4
nephrotic syndrome
4
pefloxacin
1
treatment
1
nephrotic
1
syndrome
1

Similar Publications

Article Synopsis
  • Brucellosis affects both animals and humans globally, but treating it with antibiotics, particularly fluoroquinolones, is complex due to issues like relapse and resistance.
  • Fluoroquinolones show significant benefits, including effectiveness against intracellular bacteria, low toxicity to kidneys, and no need for drug-level monitoring, which may help prevent disease recurrence.
  • A systematic review of 47 studies revealed low resistance rates to several fluoroquinolones used against brucellosis, highlighting their potential as alternative treatments for patients facing complications from other therapies.
View Article and Find Full Text PDF

Salmonella enterica subsp. enterica (Salmonella), one of the most common causes of bacterial foodborne infections, causes salmonellosis, which is usually self-limiting. However, immunocompromised individuals and children often require antimicrobial therapy.

View Article and Find Full Text PDF

Increasing resistance to first-line antibiotics used in the treatment of infections caused by Salmonella and Shigella species is emerging. Azithromycin presents a good alternative treatment option for Salmonella and Shigella infections. However, there are limited data regarding the susceptibility of azithromycin in Turkey.

View Article and Find Full Text PDF

Fluoroquinolones are broad-spectrum antibiotics that are considered as first line drugs to treat infectious diseases. In order to find out useful fluoroquinolones, the antibiotic resistance of fluoroquinolones, namely, ofloxacin (OFL), ciprofloxacin (CIP), norfloxacin (NRF), enoxacin (ENX), pefloxacin (PFL) and levofloxacin (LVF) was investigated against ninety five clinical isolates that includes Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus mirabilis. In vitro activity of these isolates was carried out by agar dilution method.

View Article and Find Full Text PDF

Present possibilities of Q fever therapy.

Klin Mikrobiol Infekc Lek

February 2006

Department of Epidemiology, Medical Faculty of P.J.Safárik University Kosice, Slovak republic.

The first-line therapy for acute Q fever is 14 to 21 days of doxycycline, or fluoroquinolones such as ofloxacin or pefloxacin. Clarithromycin is a potential effective alternative. Chronic Q fever, especially endocarditis, requires treatment for at least 18 months, with the preferred combination of doxycycline and hydroxychloroquine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!